Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures about Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2011. Investor Relations: Philippe Niemetz
Stephen T. Chen, Ph.D.PAN Consultants, Ltd.
Chairman and CEOemail: firstname.lastname@example.org
e-mail: STCACTS@yahoo.com Tel: 212-344-6464
Tel: 626-407-2570Fax: 212-618-1276 Bernard Cohen Vice President & CFO email: email@example.com Tel: 806-376-1741 ext. 16 Fax: 806-376-9301
|SOURCE Amarillo Biosciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved